[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1019060T3 - Androgensynteseinhibitorer - Google Patents

Androgensynteseinhibitorer

Info

Publication number
DK1019060T3
DK1019060T3 DK98903769T DK98903769T DK1019060T3 DK 1019060 T3 DK1019060 T3 DK 1019060T3 DK 98903769 T DK98903769 T DK 98903769T DK 98903769 T DK98903769 T DK 98903769T DK 1019060 T3 DK1019060 T3 DK 1019060T3
Authority
DK
Denmark
Prior art keywords
prostate cancer
present
benign prostatic
prostatic hypertrophy
androgen
Prior art date
Application number
DK98903769T
Other languages
Danish (da)
English (en)
Inventor
Yangzhi Ling
Angela Brodie
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1019060T3 publication Critical patent/DK1019060T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98903769T 1997-02-05 1998-02-05 Androgensynteseinhibitorer DK1019060T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/795,932 US5994334A (en) 1997-02-05 1997-02-05 Androgen synthesis inhibitors
PCT/US1998/001569 WO1998033506A1 (fr) 1997-02-05 1998-02-05 Inhibiteurs de synthese d'androgenes

Publications (1)

Publication Number Publication Date
DK1019060T3 true DK1019060T3 (da) 2007-11-12

Family

ID=25166812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98903769T DK1019060T3 (da) 1997-02-05 1998-02-05 Androgensynteseinhibitorer

Country Status (11)

Country Link
US (2) US5994334A (fr)
EP (1) EP1019060B1 (fr)
JP (2) JP5043250B2 (fr)
AT (1) ATE368466T1 (fr)
AU (1) AU6045398A (fr)
CA (2) CA2279971C (fr)
DE (1) DE69838177T2 (fr)
DK (1) DK1019060T3 (fr)
ES (1) ES2290984T3 (fr)
PT (1) PT1019060E (fr)
WO (1) WO1998033506A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
AU6087700A (en) * 1999-07-15 2001-02-05 Procter & Gamble Company, The Nitrogen-containing steroid compounds and their use to regulate hair growth
US6093421A (en) * 1999-08-31 2000-07-25 Biotics Research Corporation Maca and antler for augmenting testosterone levels
EP1832598A3 (fr) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Traitement thérapeutique des conditions de commande de récepteur androgène
EP1409512A1 (fr) * 2000-06-27 2004-04-21 Aventis Pharma S.A. Stero des 20-fluoro-17(20)-vinyliques convenant comme inhibiteurs ce la c17-20-lyase et de la 5-alpha reductase
US6413951B2 (en) 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
US20030148987A1 (en) * 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
CA2524165A1 (fr) * 2003-04-29 2004-11-11 The Miriam Hospital Inhibiteurs 11.beta.-hsd de testosterone selectifs et methodes d'utilisations
SI2428519T1 (sl) 2004-08-24 2015-07-31 Btg International Limited Sestavek za pripravo 17-vinil-triflatov kot intermediatov
WO2006072881A1 (fr) * 2005-01-10 2006-07-13 Cortendo Invest Ab Procedes et compositions pour le traitement du diabete, du syndrome metabolique et d'autres conditions
EP1976526A2 (fr) * 2006-01-10 2008-10-08 Diobex, Inc. Methodes et compositions de traitement du cancer de la prostate
BRPI0719835A2 (pt) * 2006-10-02 2014-05-06 Cortendo Invest Ab Enantiômero de cetoconazol em humanos
WO2008154402A2 (fr) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Inhibiteurs de hdac et médicaments ciblant une hormone pour le traitement du cancer
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
US8435975B2 (en) * 2007-08-24 2013-05-07 Council Of Scientific & Industrial Research Steroidal esters of 17-oximino-5-androsten-3beta-ol
WO2009039103A2 (fr) * 2007-09-17 2009-03-26 Human Pheromone Sciences, Inc. Compositions de parfums et autres compositions qui contiennent des substances d'origine naturelle se trouvant dans les coraux
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
EP2135933B1 (fr) 2008-06-20 2013-04-03 The Procter and Gamble Company Composition de lavage
KR101946297B1 (ko) 2008-12-04 2019-02-11 충시 위 고투과력을 가진 조성물 및 이의 적용
EP3023433A1 (fr) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Nouveaux promédicaments d'inhibiteurs cyp17/anti-androgènes stéroïdiens
MX2012002834A (es) 2009-09-11 2012-04-10 Bionature E A Ltd Uso de compuestos esteroides para trastornos inflamatorios y autoinmunitarios.
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
CA2807149C (fr) 2010-08-04 2017-05-02 Pellficure Pharmaceuticals, Inc. Nouveau traitement du carcinome de la prostate
NZ618019A (en) 2011-05-20 2015-03-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Antagonists of cb1 receptor.
EP3572417A3 (fr) 2011-10-14 2020-03-25 Sage Therapeutics, Inc. Composés de 19-nor prégnane disubstitués 3,3, compositions et leurs utilisations
KR101352635B1 (ko) * 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
RS55803B1 (sr) 2012-11-28 2017-08-31 Inst Nat De La Santé Et De La Rech Médicale (Inserm) 3-(4'-supstituisani)-benzil-etar derivati pregnenolona
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CA2902335C (fr) * 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Nouvelle therapie pour le carcinome de la prostate
WO2014169836A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
EP3719030B1 (fr) 2013-04-17 2024-07-10 Sage Therapeutics, Inc. Stéroïdes neuroactifs 19-nor pour l'induction de la sédation
DK2986623T3 (en) 2013-04-17 2019-03-04 Sage Therapeutics Inc 19-NOR-C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND PROCEDURES FOR USE THEREOF
WO2015010054A2 (fr) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions, et leurs utilisations
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
PL3488852T3 (pl) 2013-08-23 2021-06-28 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
AU2015331597B2 (en) 2014-10-16 2020-04-30 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
WO2016123056A1 (fr) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions et méthodes pour le traitement des troubles du snc
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
AU2017297375B2 (en) 2016-07-11 2022-09-15 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
WO2018013615A1 (fr) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées
CN107722101A (zh) * 2017-11-03 2018-02-23 郑州大学 甾体吡啶类衍生物及其制备方法和应用
CA3139554A1 (fr) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Steroides neuroactifs et compositions associees
CN111333696B (zh) * 2020-04-07 2021-09-24 华中药业股份有限公司 一种治疗痛风的化合物及其制备方法和用途
CN114344310B (zh) * 2021-12-02 2023-10-10 华中药业股份有限公司 一种治疗痛风的药物组合物及其制备方法与用途
WO2023220117A1 (fr) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Méthodes de traitement d'une cardiomyopathie dilatée et d'une insuffisance cardiaque

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2335616A (en) * 1941-11-06 1943-11-30 Parke Davis & Co Steroidal hormone intermediates and their preparation
US2664423A (en) * 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
US2707189A (en) * 1952-09-11 1955-04-26 Upjohn Co 3-keto-17beta-acetamido-4-androstene and process
NL281305A (fr) * 1961-07-24
FR1381407A (fr) * 1963-10-17 1964-12-14 Roussel Uclaf Procédé de préparation de composés tétracycliques et produits obtenus par ce procédé
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) * 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023048A1 (fr) * 1992-05-20 1993-11-25 Merck & Co., Inc. INHIBITEURS DE 5-α-REDUCTASE A BASE DE 4-AZASTEROIDES
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
CA2233084A1 (fr) * 1995-10-19 1997-04-24 Merck & Co., Inc. Inhibiteurs de 5-.alpha.-reductase a 6-aza-steroides a substitution en position 16
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
WO1998033506A1 (fr) 1998-08-06
CA2279971A1 (fr) 1998-08-06
CA2628607C (fr) 2011-06-07
PT1019060E (pt) 2007-10-03
ATE368466T1 (de) 2007-08-15
JP5043250B2 (ja) 2012-10-10
DE69838177D1 (de) 2007-09-13
AU6045398A (en) 1998-08-25
EP1019060A1 (fr) 2000-07-19
ES2290984T3 (es) 2008-02-16
DE69838177T2 (de) 2008-04-10
JP2010024238A (ja) 2010-02-04
CA2279971C (fr) 2011-07-12
US5994334A (en) 1999-11-30
EP1019060B1 (fr) 2007-08-01
CA2628607A1 (fr) 1998-08-06
EP1019060A4 (fr) 2005-04-13
JP2001510471A (ja) 2001-07-31
US6133280A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
DK1019060T3 (da) Androgensynteseinhibitorer
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1107721T1 (el) Παραγωγα τυροζινης
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
AP9901478A0 (en) Compounds for the treatment of ischemia.
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
PT880540E (pt) 17-beta-ciclopropil-(amino/oxi)-4-azaesteroides como inibidores activos de 5-alfa-redutase e c17-c20-liase de testosterona
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE3574563D1 (de) Zusammensetzungen und verbindungen zur behandlung von prostata-adenom.
WO2001028593A3 (fr) Processus de preparation de conjugues convenant pour le traitement du cancer de la prostate
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof